On 22 February 2011 the Australian Senate Legal and Constitutional Committee introduced into Federal Parliament the Therapeutic Goods Legislation Amendment (Copyright) Bill.
Australian copyright law amended to benefit generic medicines
Home/Policies & Legislation | Posted 18/03/2011 0 Post your comment
The bill will amend the Copyright Act of 1968 enabling generic manufacturers to reproduce, with a clear conscience, essential information which is provided to patients with their medicines.
This right to reproduce the information has been challenged by an originator company via the claim of alleged copyright infringement.
Any successful infringement of copyright case would mean that suppliers of generic medicines would be unable to provide information substantially similar to the originator information. This would then prevent generic companies from supplying the essential information that must accompany medicines, thereby preventing them from supplying generic medicines to the Australian market.
This bill will introduce an amendment specifically related to ‘certain medicines’ and states that there is no infringement of copyright when the supply, reproduction, publishing, communicating or adapting of the information is ‘for a purpose related to the safe and effective use of the medicine’.
The Australian Generic Medicines industry Association (GMiA) welcomed the amendment stated that this was ‘important public policy that is designed to ensure the continued supply of generic medicines to the Australian public’.
Efficient and timely market entry of generic medicines brings the public and government important benefits of more affordable medicines and contributes significantly to the sustainability of the Pharmaceutical Benefits Scheme (PBS). In the last four years the presence of a generic medicines sector has saved the PBS in excess of Aus$1.4 billion.
Source: Australian Government ComLaw, GMiA
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
EMA concept paper towards a tailored clinical approach in biosimilar development
Public consultation for the modification of the biosimilars regulation in Brazil
Comments (0)
Post your comment